BioXcel Therapeutics, Inc. (BTAI) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-17

Key Insights

BioXcel Therapeutics, Inc. granted warrants to purchase up to 1,353,729 shares of its common stock to its lenders at an exercise price of $0.01 per share.
The warrants will expire on the seventh anniversary of their issuance, and the company agreed to register the shares issuable upon exercise of the warrants.
The issuance of the warrants was done in reliance on an exemption from the registration requirements of the Securities Act, and the lenders have represented that they are acquiring the securities for investment purposes.

Want the newest filings?

This analysis covers the filing from 2026-04-17. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-01

BioXcel Therapeutics has submitted a supplemental New Drug Application to the FDA for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting with its drug IGALMI.
The FDA has accepted the application and assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 14, 2026, indicating a potential approval timeline.
If approved, IGALMI could provide an important new treatment option for patients with agitation associated with bipolar disorders or schizophrenia, potentially expanding the company's market reach and revenue opportunities.

Filed: 2026-03-27

BioXcel Therapeutics, Inc. has released its financial results for the three months and year ended December 31, 2025, providing investors with an update on the company's performance and business activities.
The company's press release indicates that it has achieved key operational and financial milestones during the reporting period, which could potentially impact investor sentiment and the stock's valuation.
Investors should closely review the financial data and business updates provided in the press release to assess the company's growth prospects and potential risks.

Filed: 2026-03-11

BioXcel Therapeutics completed a registered direct offering, raising approximately $7.8 million in gross proceeds, which could strengthen the company's financial position and support ongoing operations.
The company amended outstanding warrants, reducing the exercise price and extending the term, which may provide additional financial flexibility and incentivize warrant holders to exercise.
The participation of the Placement Agent, Rodman & Renshaw LLC, suggests third-party validation and potential access to their investor network.

Filed: 2026-02-12

BioXcel Therapeutics has completed an updated market opportunity assessment for its product IGALMI in the at-home treatment of acute agitation associated with bipolar disorders or schizophrenia.
The assessment indicates a potential addressable market of up to 86 million annual episodes of acute agitation in the at-home setting, with up to 1.8 million eligible patients.
Prescribers have expressed moderate to high interest in using IGALMI, with the potential to replace benzodiazepines that can cause dependence.

Filed: 2026-02-06

BioXcel Therapeutics has entered into milestone and retention bonus agreements with key employees, including senior management, to incentivize them and ensure their retention as the company seeks FDA approval for its IGALMI drug for the acute treatment of agitation associated with bipolar disorders or schizophrenia.
The agreements provide for substantial cash bonuses, including an initial payment and a final payment in April 2026 subject to the employees remaining actively employed and the company not defaulting on its credit agreement.
The agreements also include provisions for accelerated payment of the final bonus amount if the company raises at least $25 million in capital or experiences a change of control or other material transaction prior to April 2026.

Filed: 2026-01-20

BioXcel Therapeutics has submitted a supplemental New Drug Application (sNDA) to the FDA for the at-home use of its product IGALMI, which was previously approved for the acute treatment of agitation associated with schizophrenia or bipolar disorder under healthcare provider supervision.
If approved, the expanded label for IGALMI would provide a much-needed FDA-approved option for the at-home treatment of agitation in patients with bipolar disorders or schizophrenia.
The successful expansion of IGALMI's label could significantly increase the company's market opportunity and drive future revenue growth.

Filed: 2026-01-12

BioXcel Therapeutics, Inc. (BTAI) announced that Mark Pavao is joining the company as Interim Chief Commercial Officer to support the potential launch of IGALMI in the at-home setting.
The company plans to submit a supplemental New Drug Application (sNDA) this month seeking FDA approval of IGALMI for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia.
The company is transforming neuroscience through the strategic use of AI-driven drug discovery and human insight, reimagining existing medicines, and accelerating the development of innovative therapies to transform the standard of care in neuropsychiatry.

Other reports for BioXcel Therapeutics, Inc.

Annual Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.